A phase II trial of durvalumab and tremelimumab in metastatic, non‐urothelial carcinoma of the urinary tract

BACKGROUND: Immune checkpoint blockade has made a significant impact on the clinical outcomes of patients with metastatic urothelial carcinoma (UC). However, evidence for this approach in patients with non‐UC of the urinary tract is limited. METHODS: This was a phase II open‐label study of durvaluma...

Descripción completa

Detalles Bibliográficos
Autores principales: Sarfaty, Michal, Whiting, Karissa, Teo, Min Yuen, Lee, Chung‐Han, Peters, Vanessa, Durocher, Jennifer, Regazzi, Ashley M., McCoy, Asia S., Hettich, Grace, Jungbluth, Achim A., Al‐Ahmadie, Hikmat, Ostrovnaya, Irina, Chaim, Joshua, Bajorin, Dean F., Rosenberg, Jonathan E., Iyer, Gopa, Funt, Samuel A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7897955/
https://www.ncbi.nlm.nih.gov/pubmed/33382520
http://dx.doi.org/10.1002/cam4.3699

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7897955/
https://www.ncbi.nlm.nih.gov/pubmed/33382520
http://dx.doi.org/10.1002/cam4.3699

Ejemplares similares